surmount-1 trial tirzepatide obesity without diabetes weight loss once weekly for the treatment of in people with type 2 (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 Tirzepatide and blood pressure reduction:

Your experience will depend on your dose, your habits, and how your body responds

Hold the vial horizontally and slowly rotate it back and forth

Clinical trials have shown that these medications can result in substantial and sustained weight loss when combined with lifestyle modifications, such as a balanced diet and regular exercise

Additionally, GLP-1 drugs like tirzepatide reduce appetite, slow digestion, and may cause digestive side effects

The decision affects medication safety, effectiveness, and long-term health outcomes

Weight loss is rarely linear, and factors such as water retention, hormonal fluctuations, muscle gain, and normal metabolic adaptation can temporarily slow progress